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Effects of Conjugated Linoleic Acid and Metformin on
Insulin Sensitivity in Obese Children: Randomized
Clinical Trial
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Children and Adolescent Obesity Clinic, 2Research Unit, and 3Department of Surgery, Hospital General de
México Eduardo Liceaga, 06726 Mexico City, Mexico; 4Department of Human Genetics, Hospital General de
México Eduardo Liceaga–Facultad de Medicina, Universidad Nacional Autónoma de México, 04510 Mexico
City, Mexico; 5Specialized Center for Diabetes Control, Public Health Services, Mexico City, Mexico 11340;
6
Basic Medical Sciences Department, TEC-ABC School of Medicine, Tecnológico de Monterrey, Mexico
05300; and 7School of Medicine, South Texas Diabetes and Obesity Institute, University of Texas Rio Grande
Valley, Edinburg, Texas 78539

Context: Insulin resistance precedes metabolic syndrome abnormalities and may promote cardiovascular disease and type 2 diabetes in children with obesity. Results of lifestyle modification
programs have been discouraging, and the use of adjuvant strategies has been necessary.
Objective: This study aimed to evaluate the effects of metformin and conjugated linoleic acid (CLA)
on insulin sensitivity, measured via euglycemic-hyperinsulinemic clamp technique and insulin
pathway expression molecules in muscle biopsies of children with obesity.
Design: A randomized, double-blinded, placebo-controlled clinical trial was conducted.
Setting: Children with obesity were randomly assigned to receive metformin, CLA, or placebo.
Results: Intervention had a positive effect in all groups. For insulin sensitivity Rd value (mg/kg/min),
there was a statistically significant difference between the CLA vs placebo (6.53 6 2.54 vs 5.05 6 1.46,
P = 0.035). Insulinemia and homeostatic model assessment of insulin resistance significantly improved in the CLA group (P = 0.045). After analysis of covariance was performed and the influence of
body mass index, age, Tanner stage, prescribed diet, and fitness achievement was controlled,
a clinically relevant effect size on insulin sensitivity remained evident in the CLA group (37%) and
exceeded lifestyle program benefits. Moreover, upregulated expression of the insulin receptor
substrate 2 was evident in muscle biopsies of the CLA group.
Conclusions: Improvement of insulin sensitivity, measured via euglycemic-hyperinsulinemic clamp and
IRS2 upregulation, favored patients treated with CLA. (J Clin Endocrinol Metab 102: 132–140, 2017)

O

besity is a multifactorial disease with high prevalence in Mexico. According to the 2012 National
Survey of Health and Nutrition, the prevalence of

overweight and obese children and adolescents in
Mexico is 34% (1). Insulin resistance has been recognized as the main physiopathological event preceding
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Subjects and Methods
We performed a randomized, double-blinded, 16-week placebo
(PLB)-controlled trial in the Pediatric Obesity Clinic at the
Pediatrics Department of Hospital General de México (Mexico
City, Mexico).
Patients with obesity aged 8 to 18 years who had not been
previously intervened and had optimal psychological health
were included in the study. Obesity was defined using Centers for Disease Control and Prevention criteria [body mass
index (BMI) $ 95th percentile]. Exclusion criteria included
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BMI $ 35 kg/m2, genetic or endocrine obesity, a systemic illness,
diabetes or prediabetes (according to American Diabetes Association criteria) (15), and the use of weight loss medications
that could modify lipids and glucose concentrations. The study
(no. DI/11/311/04/108) was approved by the hospital’s institutional review board; additionally, it was registered in
ClinicalTrials.gov (no. NCT02063802).
All participants were included in the standardized healthy
lifestyle program addressed to children and their parents. This
4-month program consisted of a monthly visit that included a
1-hour structured physical activity session (coordinated by a
physical trainer), followed by a psychoeducational group session. The following information was presented to all participants: (a) description of a balanced and healthy nutrition, (b)
emotion-related eating behavior and family support, (c) the
benefits of physical activity, and (d) obesity-related comorbidities. These sessions were coordinated by nutritionists,
psychologists, pediatricians, pediatric endocrinologists, and a
physical trainer. Afterward, all patients held a medical consultation to evaluate their anthropometry and medical condition, as well as their progression and acquisition of skills and
their compliance to the program. At the beginning of the
intervention a complete nutritional evaluation was performed
and a diet based on age, pubertal stage, and physical activity
requirements, according to the World Health Organization
and Food and Agricultural Organization guidelines, was
prescribed (16). The recommended diet composition was 55%
carbohydrates, 20% proteins, 25% lipids (,7% saturated fat,
,300 mg/d cholesterol, and ,1% trans fat), and ,3 g of salt
per day. Participants filled out a 24-hour nutritional recall
questionnaire during the 3 days prior to their follow-up appointment to assess diet compliance. All patients were encouraged to participate in sports activities at last 5 days a week
and for a minimum of 60 minutes.
To evaluate physical activity compliance, we tested fitness
achievement using the Harvard step test modified for the pediatric population and a physical fitness score was calculated
(17); evaluations were applied at baseline and at the postintervention state. The overall intervention compliance was
evaluated through anthropometric, metabolic, and fitness parameter modifications, as well as through the acquisition of
healthy behavior knowledge.

Clinical trial design
This trial was conducted in accordance with the Declaration of
Helsinki and adhered to Good Clinical Practice Guidelines issued
by the International Conference of Harmonization. The children
and their parents provided written informed assent/consent. Eligible
patients were included in the lifestyle intervention program (LIP)
and randomized to receive either MET (1 g/d), CLA containing
50:50 isomers c9,t11 and t10,c12 (3 g/d), or PLB (1 g/d) 3 times a
day for 16 weeks. Visits were scheduled monthly. Diet, exercise,
and medication compliance, as well as anthropometric variables,
were recorded during each visit. The final evaluation was similar to
baseline; EHCT and skeletal muscle biopsies were performed at the
postintervention state. Patients were eliminated when they showed
poor compliance to medication (,80% or .100%) or intolerance,
or when $1 workshop sessions were missed.

Anthropometric and metabolic evaluation
Baseline evaluation consisted of complete anthropometric
and body composition analysis. Height and weight were obtained
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metabolic syndrome abnormalities and may promote
cardiovascular disease and type 2 diabetes in individuals
with obesity (2). Lifestyle modification through healthy
food selection and consumption, a regular physical activity program, and optimal sleep hygiene have been
proposed as the gold standard of care in these individuals. Unfortunately, the compliance and success of
these strategies are usually disappointing (3, 4), making
pharmacological approaches somewhat necessary.
Metformin (MET) is a biguanide used for the treatment
of type 2 diabetes in children and adolescents due to its
ability to decrease hepatic glucose production and increase
peripheral insulin sensitivity. MET has been proposed as
an adjuvant treatment in pediatric obesity efforts, especially
in the presence of insulin resistance and its comorbidities.
MET has beneficial effects on weight reduction and insulin
resistance in obese nondiabetic individuals (5, 6).
Conjugated linoleic acid (CLA) is a group of isomers of
linoleic acid, which are synthesized in the cud of ruminant
animals by fermentative bacteria (7). CLA is present in
dairy products, meat, and fat from beef and lamb. The
most common CLA isomer contained in these products is
cis-9,trans-11, which can be commercially synthesized
from linoleic acid–rich oils and prepared as a 50%
mixture with the trans-10,cis-12 isomer (8). Several
studies have acknowledged the beneficial effects of CLA
isomers on body composition (9, 10), immune response
(11), bacterial-induced colonic inflammation (12, 13), as
well as improvements in insulin sensitivity and lipid
metabolism in experimental animals and humans (9).
Additionally, CLA purportedly reduces fatty acid synthesis
in adipocytes, suggesting that this supplement decreases fat
deposition, directly contributing to an improvement in
body composition in adults and children (14). Nonetheless, the impact of CLA on human health and disease is still
controversial and research on this matter continues.
Based on the current obesity frequency in Mexico, and
considering the limited and discouraging outcomes of
intervention programs, adjuvant strategies must be installed. The objective of the present study was to evaluate
the effects of MET and CLA on insulin sensitivity,
measured via the euglycemic-hyperinsulinemic clamp
technique (EHCT), in children with obesity.

press.endocrine.org/journal/jcem
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CLA, Metformin, and Children’s Insulin Sensitivity

Clamp procedure
A 2-hour euglycemic-hyperinsulinemic clamp was performed (18) and executed during a 12-hour fasting condition.
Intravenous catheters were inserted in the right and left forearm
vein, one in a retrograde direction, and warmed in a box that
was designed for this purpose (Kepis Keipis One Device, unpublished data). This device allowed the introduction of the
complete forearm and maintenance of adequate high temperature and humidity that provided an arteriovenous shunt for
blood sample supply while avoiding burns. The additional vein
was used to infuse insulin and 20% dextrose solution at variable rates. Intravenous crystalline insulin (Humulin; Eli Lilly &
Co., Indianapolis, IN) was used. A priming insulin dose of
120 mIU/m2 of body surface (bs) per minute at time 0 was administered after 1 hour of baseline and during the first 5 minutes.
Thereafter, the infusion was gradually reduced to 60 mIU/m2bs/min
up to minute 10 and maintained through the end of the clamp.
Glucose infusion started at minute 5 (5 mg/kg/min in all the
patients according to information obtained during the standardization procedure). The samples were obtained every
5 minutes, and glucose infusion was dynamically modified to
clamp plasma glucose at 85 to 95 mg/dL.
The rate of glucose disposal (Rd) was calculated and adjusted
during the last 30 minutes of the clamp when plasma glucose
stabilized at a fixed range.
Primary endpoints included the postintervention insulin
resistance state defined as the Rd value (mg/kg/min) measured
via EHCT, as well as the evaluation of surrogate indexes of
insulin resistance and sensitivity (insulinemia, HOMA-IR, and
QUICKI). The expression of insulin receptor substrates IRS1,
IRS2, and IRS4 in muscle biopsies complemented the insulin
resistance study. Secondary objectives were modifications of
anthropometric and metabolic parameters. Moreover, medication safety and tolerability were important outcomes.

Muscle biopsies
The participation of MET and CLA on the insulin signaling
pathway was explored with muscles biopsies from the vastus
lateralis performed under local anesthesia after 16 weeks of
intervention. An incision with a no. 11 surgical blade was made
to insert an 8 swg (4.0 mm) Bergstrom needle (Ultramed,
Milton, ON, CA).

RNA isolation
Total RNA was isolated from biopsies samples using an
RNeasy fibrous tissue minikit for muscle and an RNeasy lipid
tissue minikit for adipose tissue (Qiagen, Valencia, CA) following the manufacturer’s protocol. RNA concentration was

determined using a NanoDrop 1000 spectrophotometer
(Thermo Scientific, Waltham, MA). Integrity was evaluated by
agarose gel electrophoresis using a vertical chamber Enduro
(Labnet International, Edison, NJ) and the UltraSlim LED
Illuminator SLB-01 (Maestrogen, Las Vegas, NV).

Genetic expression of insulin receptors
The genetic expression patterns of IRS1, IRS2, and IRS4
were studied in 14 and 17 muscular tissue biopsies obtained
from the MET and CLA groups, respectively. Quantitative
reverse transcription polymerase chain reaction array (human
insulin signaling pathway, RT2 Profiler, PAHS-030Z, Qiagen)
was performed. Complementary DNA was prepared using an
RT2 polymerase chain reaction array first-strand kit (Qiagen)
according to the manufacturer’s instructions. Normalization
was computed with ACTB, B2M, GAPDH, HPRT1, and
RPLP0. The expression patterns observed in the MET and CLA
groups were compared with muscular tissue samples from the
PLB group (n = 17) used as calibrator. The differential gene
expression was calculated using the Qiagen software polymerase chain reaction analyzer through the 22DDCt analysis,
and a 2.5-fold change cut-off (P , 0.05) was considered.

Statistical analysis
Descriptive statistics for all numerical variables are reported
as the mean and standard deviation and standard error of the
mean (SEM) for contrasts as indicated in the text or figures.
Contrast among treatment groups was assessed by analysis of
variance and analysis of covariance (ANCOVA) for adjustment
by confounding variables. Post hoc analysis and the multiple
contrast hypothesis corrected by Fisher’s least significant distance were executed. The h2 effect sizes obtained from
ANCOVAs were transformed to Cohen’s d. x2 Analyses were
also executed to evaluate differences in proportion among
groups. SPSS software version 22 (IBM, Armonk, NY) was used
to conduct the statistical analyses. A probability of a error
of ,5% was considered as statistically significant.

Results
Participants and demographics
Enrollment occurred from August 2012 to July 2014.
One hundred ninety-eight individuals were potentially
eligible; 83 met inclusion criteria, signed consent and
assent forms, and were randomized to receive MET
(n = 24), PLB (n = 30), and CLA (n = 29). Fifty patients
completed the 16-week intervention; 1 external outlier
was identified and excluded during the analysis (PLB
group). In 1 case, EHCT performance was technically
impossible (CLA group). For this reason, we report the
results of 48 executed clamps (Fig. 1). Throughout the
study, 1 patient was eliminated when a preexisting lipoma was surgically removed without notifying the research team (PLB group); a second patient with
psychosocial anomalies and suspected pregnancy was
eliminated as well (PLB group). Twenty-nine patients
were eliminated due to poor medication compliance or
due to lack of interest (MET, n = 10; PLB, n = 10; and
CLA, n = 9). Pubertal development (Tanner stage 1,
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with participants in light clothes and without shoes, using a
standardized stadiometer and mechanical scale. A 12-hour fasting
blood sample was drawn. Laboratory measurements included
glucose, lipid profile, and aminotransferases that were analyzed
enzymatically with the use of commercially available reagents.
Insulin was measured using Bio-Plex Pro human diabetes insulin
immunoassay by Bio-Rad (Hercules, CA). Fasting insulin resistance and sensitivity surrogated indexes were calculated as
follows: homeostatic model assessment of insulin resistance
(HOMA-IR) = [fasting plasma insulin (mU/mL) 3 fasting plasma
glucose (mmol/L)]/22.5, and quantitative insulin sensitivity check
index (QUICKI) = 1/[log fasting plasma insulin (mU/mL) +
log fasting plasma glucose (mg/dL)].

J Clin Endocrinol Metab, January 2017, 102(1):132–140

doi: 10.1210/jc.2016-2701

defined as prepubertal; Tanner stages 2 to 3, defined as
early puberty; and Tanner stages 4 to 5, defined as late
puberty) was assessed after a clinical inspection of the
mammary glands, testes volume, and pubic hair. Demographic and baseline characteristics were similar
among the groups (Table 1).
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Insulin sensitivity measured by EHCT
The primary outcome, insulin sensitivity, calculated
as the Rd value, showed significant difference between
the CLA group compared with PLB (6.53 6 2.54 vs
5.05 6 1.46, P = 0.035, Cohen’s d effect size of 74%)
(Table 3). Moreover, fasting insulinemia (Fig. 2) and
HOMA-IR (Fig. 3) significantly decreased in the CLA
group (P = 0.04). The adjusted analysis for controlling the
influence of modifying or confounding variables such as
BMI, change in BMI, age, Tanner stage, as well as dietary
and physical program compliance, over the Rd value,
showed that the Tanner stage had an independent effect over the Rd value (P , 0.001). When ANCOVA was
executed and the aforementioned variables were controlled, no statistically significant differences were found
between the three groups with regards to Rd value.
Nonetheless, a clinically relevant effect size remained evident when comparing the CLA and PLB groups (Cohen’s
d effect size of 37%), suggesting a decrease in insulin resistance in patients receiving CLA. The effect size of MET vs
PLB was 10% (5.72 6 3.1 vs 5.38 6 3) and that of MET vs
CLA was 20% (5.72 6 3.1 vs 6.34 6 2.8), favoring the

Figure 1. Flowchart representing the number of subjects at study enrollment and study termination. Fourteen clamp studies were conducted in
the PLB group, 17 in the MET-treated group, and 17 in the CLA-treated group.
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Anthropometric and metabolic results
No significant differences were observed in baseline
anthropometric and metabolic parameters or insulin
resistance measured by surrogate indexes of insulin resistance (fasting insulinemia, HOMA-IR, and QUICKI).
Distribution of Tanner stage status did not differ among
the groups (x2 test, P = 0.415).
The overall impact of the intervention showed a positive
effect on weight, height, BMI, and waist circumference, as
well as on surrogated indexes of insulin resistance and
physical fitness score in all of the groups (Table 2). No
statistically significant differences were observed in these
parameters between treatment groups. No differences were
evident when comparing surrogate indices of insulin resistance during the postintervention phase among the groups.

press.endocrine.org/journal/jcem
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Table 1.

CLA, Metformin, and Children’s Insulin Sensitivity

J Clin Endocrinol Metab, January 2017, 102(1):132–140

Participant Characteristics at Randomization
MET (n = 14)
11.43
63.25
148.4
28.54
87.12
87
167
41
107
150
81
43.5
9.42
0.63

(2.1)
(12.6)
(10)
(2.8)
(7.6)
(7)
(27)
(10)
(24)
(62)
(56)
(22)
(4)
(0.08)

12.59
70.15
153.4
28.79
89.43
87
167
37
106
161
83
37.1
8.07
0.64

CLA (n = 17)

(2.62)
(13.11)
(12)
(2.8)
(8.45)
(8.2)
(28)
(8)
(24)
(60)
(45)
(17)
(4)
(0.06)

11.41
62.11
148.6
27.48
87.17
85
162
38
100
159
85
42.5
9.2
0.66

P

(2.71)
(18.47)
(13)
(3.7)
(11.2)
(8.1)
(23)
(8)
(25)
(84)
(66)
(27)
(6)
(0.15)

0.31
0.26
0.42
0.45
0.71
0.62
0.79
0.42
0.67
0.89
0.98
0.25
0.68
0.54

Data are expressed as mean (standard deviation).
Abbreviation: LDL, low-density lipoprotein.

CLA-treated group. However, these effect sizes were not
clinically relevant.
We analyzed the changes between initial and final
serum triglycerides and high-density lipoprotein (HDL)
cholesterol by ANCOVA. For these particular variables,
no Tanner or change in BMI modified postintervention
levels. Furthermore, HDL cholesterol and triglyceride
baseline levels did show an influence over the final levels.
Lipid profile and adverse effects
Patients in the CLA group had a statistically significant
increase in serum triglycerides when compared with MET
(169.8 6 69 vs 113.1 6 27, P = 0.027), but not significant
when compared with PLB (P = 0.13). Moreover, HDL
levels were lower in the CLA group when compared with
MET (36.8 6 5.4 vs 44.86 6 8.7, P = 0.009), whereas
there were no differences when compared with PLB
(P = 0.26). The main differences favoring MET treatment

over the lipid profile were evident only when compared
with CLA.
Nonserious adverse events most commonly reported
were abdominal pain, diarrhea, dizziness, headache,
nausea, and gastritis. The frequency and severity of
symptoms were similar in the three groups (analysis of
variance, P = 0.314; x2 test, P = 0.28). Patients exhibiting
lack of compliance and/or dropout did not show a difference between groups. Additionally, a Little’s missing
completely at random analysis (P . 0.13) was conducted
to ensure that patient elimination was actually random
and homogeneous in all of the groups.
Muscle biopsies’ analyses
The analyses of IRS1, IRS2, and IRS4 revealed that
only IRS2 was modulated in the CLA group, showing
a 3.56-fold increase compared with the control group
(P = 0.043). The rest of the genes did not show statistically

Table 2. Overall Impact of Intervention Regarding Anthropometric, Metabolic, and Insulin Resistance
Outcomes in All Patients
Baseline (n = 48)
Weight, kg
Height, cm
BMI, kg/m2
Waist circumference, cm
Glucose, mg/dL
Total cholesterol, mg/dL
HDL cholesterol, mg/dL
LDL cholesterol, mg/dL
Triglycerides, mg/dL
Insulin, mU/mL
HOMA-IR
QUICKI
Physical fitness score (Harvard test)

65.29
150.2
28.25
87.9
87
167
39.2
105
154
40.9
8.86
0.64
83.82

(2.2)
(1.75)
(0.45)
(1.32)
(1.13)
(3.75)
(1.27)
(3.53)
(9.96)
(3.26)
(0.77)
(0.01)
(7.96)

4 Months Postintervention (n = 48)
62.51
151.7
26.56
83.8
85
161
40.4
100
139
34.5
7.27
0.68
124.0

The P values were determined by a paired-samples Student t test. Data are expressed as mean (SEM).
Abbreviation: LDL, low-density lipoprotein.

(2.15)
(1.66)
(0.51)
(1.24)
(0.85)
(4.21)
(1.21)
(3.57)
(9.73)
(2.95)
(0.63)
(0.01)
(5.44)

P
,0.001
,0.001
,0.001
,0.001
0.28
0.07
0.24
0.056
0.22
0.025
0.018
0.014
,0.001

Downloaded from https://academic.oup.com/jcem/article/102/1/132/2804736 by guest on 06 October 2021

Age, y
Weight, kg
Height, cm
BMI, kg/m2
Waist circumference, cm
Glucose, mg/dL
Total cholesterol, mg/dL
HDL cholesterol, mg/dL
LDL cholesterol, mg/dL
Triglycerides, mg/dL
Physical fitness score (Harvard test)
Insulin, mU/mL
HOMA-IR
QUICKI-IS

Placebo (n = 17)

doi: 10.1210/jc.2016-2701

Table 3.
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Characteristics of Main Interest Variables After 4 Months of Intervention
MET (n = 14)
60.85
149.89
26.17
82.31
92.04
103.82
5.57
40.5
8.53
0.65
44.86
113.14

(3.41)
(2.45)
(0.99)
(1.87)
(6.15)
(16)
(0.47)a,b
(6.37)
(1.36)
(0.02)
(2.33)a
(7.26)b

66.48
154.82
27.53
84.96
83.78
132.9
5.05
32.3
6.83
0.69
40.00
134.12

(3.19)
(2.82)
(0.78)
(1.77)
(6.21)
(13.09)
(0.35)b
(4.11)
(0.88)
(0.02)
(2.15)a,b
(20.36)a,b

CLA (n = 17)
59.91
150.27
25.92
83.92
83.09
132.79
6.53
31.6
6.68
0.71
36.876
169.80

(4.34)
(3.19)
(0.90)
(2.68)
(3.56)
(14.61)
(0.61)a
(5.05)
(1.08)
(0.02)
(1.35)b
(15.93)a

P
0.39
0.40
0.37
0.70
0.43
0.29
0.035
0.42
0.45
0.38
0.031
0.027

Data are expressed as mean (SEM).
a,b

Homogeneous groups by Fisher’s least significant difference contrast.

significant differences. These data support the fact that
CLA has a critical effect in the molecular insulin pathway
through the upregulation of ISR2. This mechanism might
be related to optimal glucose uptake observed in CLAtreated patients.

Discussion
This study supports that CLA improves insulin sensitivity, as measured by EHCT in a group of obese children,
and exceeds LIP benefits.
Because the prevalence of metabolic syndrome in our
pediatric clinic averages 35% and confers an 11-fold risk
of diabetes during early adult life (19), the exploration of
conventional and pharmacological strategies focusing on
improving the insulin sensitivity level is imperative. Recent studies have revealed that MET has important effects
on insulin sensitivity when compared with PLB, and its
use in nondiabetic, obese individuals has been massively
extended (6, 20, 21). A systematic review conducted by
Brufani et al. (6) revealed a significant but moderate
benefit of MET on weight reduction and fasting insulin
sensitivity compared with PLB or lifestyle interventions
alone. Nonetheless, when these outcomes were evaluated
by frequently sampled intravenous glucose tolerance test
(22) or hyperglycemic clamp technique (23), no significant differences were reported. Wiegand et al. (5) demonstrated in a randomized PLB-controlled trial a
beneficial effect of MET on the insulin sensitivity index in
obese, insulin-resistant adolescents; however, no differences in body composition, weight, or BMI were found.
We found in our study a significant improvement in all
anthropometric parameters, including weight, BMI, waist
circumference, and body composition (fat mass and fat-free
mass, data not shown); nonetheless, these results were not
significantly different among the treatment groups. To our
knowledge, no randomized PLB-controlled trial using

EHCT had been executed for the evaluation of MET
benefits on insulin sensitivity in children. In the present
study, we found no differences on Rd value (mg/kg/min)
when comparing MET and PLB in the postintervention
period. These data could be consistent with the final results
of the Diabetes Prevention Program Research Group (24)
that showed that diabetes incidence was better reduced in a
LIP group compared with PLB. Nonetheless, improvement
in terms of BMI, waist circumference, HDL cholesterol,
and triglycerides, with considerable effect sizes (72%,
65%, 37%, and 55%, respectively), favored patients
treated with MET in our study.
Several studies have proposed beneficial effects of CLA
isomers on body composition, inflammation, and insulin
sensitivity, promoting differentiation, lipid metabolism
regulation, and apoptotic mechanisms in adipocytes
(10–12). Interestingly, evidence has suggested that the
trans-10,cis-12 isomer of CLA might induce insulin resistance, whereas the CLA mixture has beneficial effects
on body composition and insulin sensitivity. Risérus et al.
(25) demonstrated that trans-10,cis-12 isomer–treated
subjects presented insulin and glucose increases and decreased HDL and insulin sensitivity measured by 2-hour
EHCT compared with PLB or CLA mixture-treated
groups. No differences were observed when comparing
PLB and CLA mixture-treated individuals. In our study,
we showed that the CLA mixture was associated with a
clinically relevant effect size (37%) over the Rd value of
insulin sensitivity. The confounding variables included in
the ANCOVA model showed a decline on group differences. Among these adjustments, Tanner stage was the
main variable that modified insulin sensitivity, and despite our small sample size, the effect size of CLA on the
Rd value remained.
Despite the fact that several CLA isomers might have
deleterious effects on insulin sensitivity and resistance,
certain mixtures may neutralize negative effects and even
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Weight, kg
Height, cm
BMI, kg/m2
Waist circumference, cm
Prescribed diet compliance, %
Physical fitness score (Harvard test)
Rd value, mg/kg/min
Insulin, mU/mL
HOMA-IR
QUICKI-IS
HDL cholesterol
Triglycerides, mg/dL

Placebo (n = 17)
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induce a synergistic positive response on these parameters, as well as on metabolic and anthropometric values.
Some effects of the trans-10,cis-12 isomer promote a
blunted glucose uptake that depends on decreased
expression of glucose transporter 4 (GLUT-4) (26).
Moreover, decreased incorporation of free fatty acids
into the cells may be induced by CLA, a mechanism that
could be related to diminished expression of peroxisome
proliferator-activated receptor-g in adipocytes (27). CLA
has been proposed as an apoptotic accelerator of adipocytes in mammals that liberates and increases fatty acid
oxidation elsewhere in the body (28). Evidence of deleterious effects has mainly been reported in animal models,
in which administered doses of CLA are superior to those
used in humans (0.2 to 3 g/kg vs 0.015 to 0.1 g/kg, respectively) (29). These effects, if present in humans, could
be hyperglycemia and hyperlipidemia, which may predispose an individual to diabetes and nonalcoholic fatty
liver disease (30, 31). However, few studies have been
published regarding the molecular mechanisms of CLA in
skeletal muscle that could explain increased glucose
uptake in our treated patients. On this matter, Vaughan
et al. (32), using a rabdomyosarcoma cell line, have reported that omega-3 fatty acids and CLA activate mitochondrial proliferation and glycolytic activation
pathways probably by apoptosis induction and subsequent upregulation of GLUT-4. Furthermore, animal
models have shown the beneficial effects of CLA on insulin sensitivity and overexpression of peroxisome
proliferator-activated receptor-g and GLUT-4 in the
muscle of supplemented rats (27). In the present study we

were able to demonstrate that postintervention IRS2
expression in the skeletal muscle was significantly
upregulated in CLA-treated patients. To our knowledge,
no studies have been published regarding the effects of
CLA or CLA–isomer mixtures on insulin receptor substrate molecules. Xu et al. (33) reported that MET
upregulates insulin receptor b expression and the
downstream IRS2/phosphatidylinositol 3-kinase/Akt
signaling transduction in an insulin-resistant rat model
of nonalcoholic steatohepatitis and cirrhosis. Our results
evidenced a nonsignificant but marginal (P = 0.055) IRS2
upregulation in MET-treated children. The insulinsensitizing effects of MET have been mainly described
in liver tissue. Although CLA effects have been mainly
focused on adipose tissue modeling, the present study
demonstrates that molecular mechanisms, particularly
IRS2 upregulation, might mediate insulin-sensitizing effects on skeletal muscle. This phenomenon could explain
the increased glucose infusion rate tolerability in our
patients treated with CLA throughout the EHCT.
Moreover, significant HOMA-IR improvement observed
only in CLA-treated patients denotes a significant performance in skeletal muscle that promotes a lower
pancreatic insulin secretion.
A recently published meta-analysis demonstrated that
the deleterious effects of CLA consumption might be negligible, whereas its benefits, although subtle, seem to be
clinically relevant regarding weight and fat mass loss (34).
In our study, BMI improvement was significant in all
groups, although not significantly different among them.
Nonetheless, MET displayed the highest effects over BMI
(72%, compared with 43% in the PLB group and 41% in

Figure 3. HOMA-IR was significantly lower in the CLA-treated
group at study termination compared with initial values. No
differences were found in the MET-treated and control groups. The
error bars show SEM.
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Figure 2. Fasting insulin serum concentrations were significantly
lower in the CLA-treated group at study termination, whereas no
differences were found in the MET-treated patients or in the PLB
group. The error bars show SEM.
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Conclusions
The current study demonstrates the benefits of an LIP and
additional effect of CLA over the gold standard EHCT.
Lifestyle intervention, independent of any treatment,
showed effects on the main outcome variables, specifically weight, height, BMI, waist circumference, surrogate
indexes of insulin resistance, and fitness condition, in all
of the groups. IRS2 upregulation was evident in CLAtreated patients; this mechanism might be involved in
insulin-sensitizing effects on skeletal muscle.
Finally, the incidence of hypertriglyceridemia and
hypo-a-lipoproteinemia in CLA-treated patients might
be a concern and may be related to the types of CLA
isomers used in this study. Further research to evaluate
the benefits of different mixtures of CLA isomers may be
warranted.
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